Breaking News
November 21, 2017 - Hospital Midwives, Lower C-Section Rates?: MedlinePlus Health News
November 21, 2017 - Seven body organs you can live without
November 21, 2017 - Simple test could help predict best treatment for cystic fibrosis patients
November 21, 2017 - Diabetes patients’ immune system can regulate insulin production
November 21, 2017 - Simple mirror technique boosts the performance of diSPIM, study says
November 21, 2017 - FDA raids Florida stores that consumers use to buy drugs from Canada
November 21, 2017 - FDA Alert: Limbrel Capsules by Primus Pharmaceuticals: FDA Advisory
November 21, 2017 - Exploring the genetics of glaucoma and retinal development
November 21, 2017 - Study finds sensors to detect biomarkers
November 21, 2017 - Researchers develop simple test to predict T2D remission after bariatric surgery
November 21, 2017 - Penn researchers find evidence of new malaria species in wild bonobos
November 21, 2017 - Review examines effectiveness of lipid-based products to treat dry eye disease
November 21, 2017 - Pioneering research project aims to develop better diagnostic tests for NAFLD
November 21, 2017 - The Best and Worst Ways to Say ‘I Love You’
November 21, 2017 - Even Partial Breast-Feeding for First Few Months Lowers SIDS Risk: MedlinePlus Health News
November 21, 2017 - Researchers identify protein that plays key role in diabetic blindness
November 21, 2017 - Sensors for identifying biomarkers could help detect myriad of diseases at early stages
November 21, 2017 - ‘Chemo brain’ may start as tumors form and develop, suggests study
November 21, 2017 - Scientists develop new method to study Creutzfeldt-Jakob disease in the lab
November 21, 2017 - Researchers identify previously unknown breast cell types
November 21, 2017 - Probing living cells with AFM
November 21, 2017 - Streamlined method for using CGM helps patients with diabetes maintain safe, stable glucose levels
November 21, 2017 - Even Advanced Breast Cancer Patients Gain From Exercise: MedlinePlus Health News
November 21, 2017 - Study in mice finds dietary levels of genistein may adversely affect female fertility
November 21, 2017 - Disordered eating has detrimental effects to long-term health of young adults, study finds
November 21, 2017 - Babies know more than we think they do find researchers
November 21, 2017 - New technique may reveal clues about role of centromeres in Down syndrome, other birth defects
November 21, 2017 - IUD May Lower Cervical Cancer Risk: MedlinePlus Health News
November 21, 2017 - U.S. preemie birth rates rise two years in a row
November 21, 2017 - Heart rate variability measured by electrocardiogram can help differentiate bipolar from major depression
November 21, 2017 - $10 million gift creates new center at Northwestern University to study effects of environment on genes
November 21, 2017 - Uncontrolled lung diseases could lead to costly A&E visits and hospital stays
November 21, 2017 - New study explores patients’ and family members’ views on overlapping surgeries
November 21, 2017 - KNAUER celebrates 55th anniversary and awards science prize
November 21, 2017 - Researchers find new way to boost cancer-destroying ability of T-cells
November 21, 2017 - Maintaining adequate vitamin D may help prevent onset of inflammatory diseases
November 21, 2017 - What NPs Can Do in the Opioid Crisis
November 21, 2017 - Gun Injuries Getting More Severe, Experts Say: MedlinePlus Health News
November 21, 2017 - That music playing in your head is a real conundrum for scientists
November 21, 2017 - Researcher awarded $1.5 million to study role of tumor necrosis factor in IBD
November 21, 2017 - Digital pills can help track opioid use patterns
November 21, 2017 - UZH leads Europe’s largest research on aging
November 21, 2017 - Experts endorse recommendations for restrictive blood transfusions
November 21, 2017 - New Hemophilia A Treatment, Hemlibra (Emicizumab-kxwh), Stems Bleeding Episodes
November 21, 2017 - Shining a light on the nervous system to thwart disease
November 21, 2017 - Use of Prostate Health Index cuts down need for uncomfortable biopsies
November 21, 2017 - Drugstore pain pills as effective as opioids in ER patients
November 21, 2017 - Experts explain why lead found in fidget spinners is no idle threat
November 21, 2017 - Over-the-counter decongestant found to be effective inhibitor of tumor stroma
November 21, 2017 - Anticholinergic Cognitive Burden Scale shows dose-response relationship with adverse outcomes
November 21, 2017 - Non-vitamin K antagonist oral anticoagulants linked to reduced kidney risks
November 21, 2017 - New technique holds promise to screen cancer cells for drug susceptibility
November 21, 2017 - AstraZeneca wins US approval for lymphoma drug
November 21, 2017 - Mother’s diet can protect nursing newborns against food allergies, research shows
November 21, 2017 - Cystic fibrosis patients have more good and bad bacteria in their lungs, study finds
November 21, 2017 - Patient-centered medical home model effective at improving chronic disease outcomes
November 21, 2017 - Enterovirus vaccine protects against virus-induced diabetes in mouse model
November 20, 2017 - First-of-its-kind study combines smoking cessation with personalized medicine
November 20, 2017 - FDA Approves Sutent (sunitinib malate) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma
November 20, 2017 - Researchers produce the first draft cell atlas of the small intestine
November 20, 2017 - Study explores feasibility of mainstreaming genetic counseling for ovarian cancer
November 20, 2017 - AAP and The Obesity Society jointly address weight stigma in childhood obesity
November 20, 2017 - Researchers identify three specific molecules that accurately indicate pre-diabetes
November 20, 2017 - Study estimates health care costs, injuries, and deaths due to motorcycle accidents
November 20, 2017 - Face It: Drinking, Smoking Takes Toll on Looks
November 20, 2017 - Women have lower tolerance to alcohol following gastric sleeve surgery, study finds
November 20, 2017 - Salt, inflammation and hypertension
November 20, 2017 - Electrochemistry method provides easy access to important classes of compounds
November 20, 2017 - Cancer drugs may offer new way to control high blood pressure
November 20, 2017 - Small molecules in saliva may offer clues to diagnose and predict duration of concussions
November 20, 2017 - New poll demonstrates challenge of finding childcare options that meet parent’s safety criteria
November 20, 2017 - Canadians root for an underdog U.S. health policy idea
November 20, 2017 - KAIST researchers identify principles of gene network for colon tumorigenesis
November 20, 2017 - Pregnant mother in a coma wakes three months after delivery
November 20, 2017 - VTT researcher develops disposable optical test substrate for microbial detection
November 20, 2017 - Benzodiazepines linked to increased risk of death among Alzheimer’s disease patients
November 20, 2017 - Women are advised that sleeping on their side could reduce stillbirth risk
November 20, 2017 - The skinny on lipid immunology
November 20, 2017 - Study sheds light on changes in young people’s sexual practices
November 20, 2017 - Study highlights need for early identification, treatment of PTSD in cancer survivors
Dynavax Announces FDA Approval of Heplisav-B for Prevention of Hepatitis B in Adults

Dynavax Announces FDA Approval of Heplisav-B for Prevention of Hepatitis B in Adults

image_pdfDownload PDFimage_print

Dynavax Announces FDA Approval of Heplisav-B for Prevention of Hepatitis B in Adults

BERKELEY, CA — (Marketwired) — November 9, 2017 — Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved Heplisav-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Heplisav-B is the first new hepatitis B vaccine in the United States in more than 25 years and the only two-dose hepatitis B vaccine for adults.

Hepatitis B is an extremely infectious and potentially deadly virus affecting a wide range of adults in the United States. There is no cure for hepatitis B, and infections are on the rise. In 2015, new cases of acute hepatitis B increased by more than 20 percent nationally.(i) Hepatitis B can be prevented through effective vaccination. Current hepatitis B vaccines require three shots over a six-month period, however, almost half of adults fail to complete the series within one year.(ii)

“Prevention of hepatitis B in adults through vaccination is more important than ever given the increase in the rate of infections,” said William Schaffner, M.D., professor of Preventive Medicine, Vanderbilt University Medical Center. “Too many at-risk adults remain unprotected against this virus. A two-dose schedule with higher rates of protection, along with other strategies, may help us move closer to the goal of eliminating hepatitis B as a public health problem in the United States.”

The approval of Heplisav-B was based on data from three Phase 3 non-inferiority trials of nearly 10,000 adult participants who received Heplisav-B. The pivotal studies compared Heplisav-B administered in two doses over one month to Engerix-B administered in three doses over a six-month schedule. Results from the largest Phase 3 trial, which included 6,665 participants, showed that Heplisav-B demonstrated a statistically significantly higher rate of protection of 95% compared with 81% for Engerix-B. In a subgroup analysis of 961 participants with Type 2 diabetes, Heplisav-B demonstrated a statistically significantly higher rate of protection of 90% compared to 65% for Engerix-B. Across the three clinical trials, the most common local reaction was injection site pain (23% to 39%). The most common systemic reactions were fatigue (11% to 17%) and headache (8% to 17%).

“Heplisav-B is the first FDA-approved product for Dynavax and demonstrates our ability to develop innovative products and progress them from discovery to commercialization,” said Eddie Gray, chief executive officer of Dynavax. “We would like to thank the many study participants and clinical trial investigators who contributed to the development of Heplisav-B. We expect that it will become an essential tool in the public health community’s fight to prevent hepatitis B, and we look forward to making Heplisav-B available to clinicians and their adult patients.”

Dynavax expects to commercially launch Heplisav-B in the United States in the first quarter of 2018. In preparation for launch, Dynavax has been building commercial infrastructure and optimizing manufacturing processes to meet anticipated demand.

About Hepatitis B

Hepatitis B is a viral disease of the liver that can become chronic and lead to cirrhosis, liver cancer and death. The hepatitis B virus is 50 to 100 times more infectious than HIV,(iii) and transmission is on the rise. There is no cure for hepatitis B, but effective vaccination can prevent the disease. In adults, hepatitis B is spread through contact with infected blood and through unprotected sex with an infected person. The CDC recommends vaccination for those at high risk for infection due to their jobs, lifestyle, living situations and travel to certain areas.(iv) Because people with diabetes are particularly vulnerable to infection, the CDC recommends vaccination for adults age 19 to 59 with diabetes as soon as possible after their diagnosis, and for people age 60 and older with diabetes at their physician’s discretion.(v) Approximately 20 million U.S. adults have diabetes, and 1.5 million new cases of diabetes are diagnosed each year.(vi)

About Heplisav-B

Heplisav-B is an adult hepatitis B vaccine that combines hepatitis B surface antigen with Dynavax’s proprietary Toll-like Receptor (TLR) 9 agonist to enhance the immune response. Dynavax has worldwide commercial rights to Heplisav-B.

Indication and Use

Heplisav-B is indicated for active immunization against infection caused by all known subtypes of hepatitis B virus. Heplisav-B is approved for use in adults 18 years of age and older.

Important Safety Information

Do not administer Heplisav-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of Heplisav-B, including yeast.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of Heplisav-B.

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to Heplisav-B.

Hepatitis B has a long incubation period. Heplisav-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common patient reported adverse reactions reported within 7 days of vaccination were injection site pain (23% to 39%), fatigue (11% to 17%) and headache (8% to 17%).

About Dynavax

Dynavax is a commercial-stage biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company’s first commercial product, HEPLISAV-B, a hepatitis B vaccine for adults, is approved in the United States. Dynavax’s lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the commercial launch and manufacturing of Heplisav-B. These statements are subject to a number of risks and uncertainties that could cause actual results to differ materially, including whether the company will be able to build the commercial infrastructure required to launch Heplisav-B; whether we will launch Heplisav-B in the first quarter of 2018; whether we will be able to ramp up manufacturing activities to meet demand for Heplisav-B; whether the CDC’s Advisory Committee on Immunization Practices (ACIP) will add Heplisav-B to its adult vaccination schedule during its February 2018 meeting, or at all; whether potential claims against us, including those based on patent rights of others, will result in an injunction against sales or otherwise impact commercialization and sales; and the results of clinical studies of Dynavax’s product candidates, such as SD-101, and the impact of those results on the initiation or continuation of subsequent studies for those product candidates, and issues arising in the regulatory process; and other risks detailed in the “Risk Factors” section of our most recent current periodic report filed with the SEC. These statements represent our estimates and assumptions only as of the date of this press release. We do not undertake any obligation to update publicly any such forward-looking statements, even if new information becomes available. Information on Dynavax’s website at www.dynavax.com is not incorporated by reference in our current periodic reports with the SEC.

(i) CDC. https://www.cdc.gov/hepatitis/statistics/2015surveillance/index.htm#tabs-5-8. Fig 3.2

(ii) Nelson J, et al. Compliance with multiple-dose vaccine schedules among older children, adolescents and adults: results from a Vaccine Safety Datalink Study. American Journal of Public Health. 2009;99:S2.

(iii) CDC. https://www.cdc.gov/hepatitis/hbv/bfaq.htm.

(iv) CDC. https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm.

(v) CDC. https://www.cdc.gov/diabetes/pubs/pdf/hepb_vaccination.pdf.

(vi) CDC. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf.

Source: Dynavax Technologies

Posted: November 2017

Related Articles:

  • Dynavax Provides U.S. Regulatory Update on Heplisav-B Following FDA Advisory Committee Meeting – August 3, 2017
  • Dynavax Announces FDA Advisory Committee Vote in Favor of Heplisav-B – July 28, 2017
  • Dynavax Receives Complete Response Letter from U.S. FDA for Biologics License Application for Heplisav-B – November 14, 2016
  • Dynavax Provides Regulatory Update on Heplisav-B – October 4, 2016
  • Dynavax Reports Feedback From FDA Meeting Regarding Heplisav Biologic License Application – June 10, 2013
  • Dynavax Receives FDA Complete Response Letter on Heplisav Biologic License Application – February 25, 2013
  • Dynavax Announces FDA Advisory Committee Meeting Outcome for Heplisav – November 16, 2012
  • Dynavax Announces FDA Advisory Committee to Review Heplisav – August 29, 2012
  • Dynavax Announces FDA Acceptance of Heplisav BLA – June 27, 2012
  • Dynavax Reports Heplisav BLA Submission – April 27, 2012

Heplisav-B (hepatitis B vaccine, recombinant (adjuvanted)) FDA Approval History

Tagged with:

About author

Related Articles